Estradiol for Menopause: Evidence, the 2025 Label Change, and Safety

Estradiol is bioidentical estrogen, chemically identical to the 17-beta-estradiol the ovaries produce before menopause. It is prescribed to treat moderate to severe hot flashes and night sweats, together called vasomotor symptoms, and to treat the genitourinary syndrome of menopause, which covers vaginal dryness, irritation, and painful sex. It is also approved to prevent bone loss after menopause.

Two routes are emphasized here: the transdermal patch, which sticks to the skin and is changed once or twice a week, and the gel, which is rubbed into the skin daily. Both deliver estradiol through the skin into the blood. An oral estradiol pill also exists and works, but the route changes the safety profile, covered below in the section on transdermal versus oral. A reader weighing the formats can read more in this comparison of the estradiol patch, gel, and pill.

Estradiol works by replacing the estrogen lost at menopause and acting on estrogen receptors throughout the body. These receptors sit in the brain's temperature center, the vaginal and urinary tissue, and bone. When ovarian estradiol falls at menopause, those tissues lose their signal, which produces hot flashes, vaginal thinning, and faster bone breakdown.

Supplying estradiol restores the signal. In the brain it steadies the temperature set point, which reduces hot flashes. In the genitourinary tissue it restores thickness and moisture. In bone it slows the cells that break bone down, which preserves density. It is hormone replacement in the literal sense, returning a hormone to a level closer to the premenopausal range, not adding a foreign drug.

The FDA in November 2025 began removing the broad boxed warning from menopausal estrogen products, but it did not remove every warning. After a scientific review, an expert panel, and a public comment period, the agency moved to drop the boxed-warning language on cardiovascular disease, breast cancer, and probable dementia, which it judged misleading for most women treating menopausal symptoms. You can read a fuller account in this explainer on the 2025 HRT label change.

One warning stays. The FDA kept the boxed warning for endometrial cancer on systemic estrogen-alone products. Its reasoning is direct: a woman with a uterus who takes estrogen without a progestogen faces a higher risk of endometrial hyperplasia and uterine cancer. So the change is partial, not total. It is wrong to say all warnings were removed.

The agency also said new labels would carry age-specific guidance, reflecting evidence that women may gain long-term benefit when therapy starts within 10 years of menopause.

The risks that built the original warning came from one large trial whose design limits how far the numbers travel. The Women's Health Initiative randomized more than 16,000 women to either a hormone combination or placebo and was stopped early in 2002 when the hormone arm showed more breast cancers and cardiovascular events (Rossouw 2002). Those headline findings drove the boxed warning and the collapse in use. The persistence of WHI-driven fear, set against the later reanalysis, is covered in this look at the WHI study and the myths around it.

Two design facts matter. First, the trial used oral conjugated equine estrogens combined with medroxyprogesterone acetate, not transdermal estradiol, so its results do not transfer cleanly to a patch or gel. Second, the average participant was 63 years old, more than a decade past menopause, an age at which baseline cardiovascular risk is already higher.

The absolute risks help put it in scale. In a later analysis of the combined-hormone arm, the changes worked out to about 8 more breast cancers, 8 more strokes, and 6 fewer colorectal cancers per 10,000 women per year (Manson 2013). These are small absolute numbers, and they describe an older oral formulation, not the typical estradiol patch started near menopause.

When estradiol is started changes its risk and benefit balance. Evidence points to a timing effect: estrogen begun near menopause behaves differently from estrogen begun many years later. The North American Menopause Society states that for healthy women younger than 60, or within 10 years of menopause onset, with no contraindications, the benefit outweighs the risk for treating vasomotor symptoms and preventing bone loss (NAMS 2022).

The same statement notes the reverse for late starters. Women who begin hormone therapy after age 60, or more than 10 to 20 years past menopause, carry higher absolute risks of heart disease, blood clots, and stroke than women who start in early menopause. This is why age and time since menopause weigh heavily in the decision, and why the WHI population, older on average, is a poor stand-in for a woman in her early fifties.

The patch and gel skip a metabolic step that the pill does not, and that difference lowers clot risk. An oral estradiol pill passes through the liver before reaching the rest of the body, the so-called first-pass effect, which raises the liver's output of clotting factors. The patch and gel deliver estradiol through the skin straight into the blood, bypassing that first pass.

The clinical signal follows the biology. In the French ESTHER study, women using transdermal estrogen had a lower risk of venous blood clots than women using oral estrogen, whose risk was raised compared with non-users (Canonico 2007). This is observational evidence, not a randomized trial, so it shows an association rather than proof. Still, the consistency with the known liver mechanism is why transdermal estradiol is often preferred for women with clot risk factors.

Whether estradiol is taken alone depends on whether a woman still has her uterus. Estrogen on its own stimulates the uterine lining, which over time raises the risk of endometrial hyperplasia and cancer. This is the exact risk behind the one boxed warning the FDA kept in 2025.

A woman with a uterus is therefore prescribed a progestogen alongside estradiol to protect the lining. Micronized progesterone is one common choice. A woman who has had a hysterectomy has no uterine lining to protect and can use estrogen alone, which is why estrogen-alone products exist at all. The reasoning behind pairing the two is laid out in this piece on why progesterone is needed with estrogen.

Most side effects of estradiol are mild, and the serious ones are uncommon and tied to the factors above. Common effects include breast tenderness, headache, nausea, and irregular bleeding or spotting, especially in the first months. The patch can cause skin irritation where it sits. These usually settle as the body adjusts or with a change in dose or route.

The serious risks are blood clots, stroke, and, with estrogen plus a progestogen, a small rise in breast cancer over years of use. The absolute size of those risks, from the WHI combined arm, was about 8 more breast cancers and 8 more strokes per 10,000 women per year, in an older oral-formulation population (Manson 2013). For a healthy woman starting transdermal estradiol near menopause, the relevant risk is lower than those numbers suggest, which is the basis for the 2025 label change and the NAMS position.

Estradiol is not safe for everyone. It should not be used by anyone with:

• Known, suspected, or past breast cancer or another estrogen-dependent cancer
• Undiagnosed abnormal vaginal bleeding
• Active or past venous blood clots, such as deep vein thrombosis or pulmonary embolism
• Active or recent arterial clot disease, such as stroke or heart attack
• Active liver disease
• Known or suspected pregnancy

A clinician reviews these conditions before prescribing, because they shift the balance from benefit toward harm. Some, such as a clot history, may steer the choice toward transdermal rather than oral estradiol rather than ruling out treatment entirely. That judgment belongs in the visit, with the full history in front of the prescriber.